Elevance Health
ELV (NYSE)
Elevance Health (ELV) has demonstrated strong momentum, recently hitting a six-month high and surpassing its 200-day moving average, making it a top-rated choice for investors seeking growth potential in 2026. Despite a 1-year return of -5.43%, the stock's 5-year return of 12% and a dividend yield of 2.07% highlight its appeal for value investors. Analysts have a positive outlook, with a median 12-month price target of $402, suggesting room for growth.
Pros:
- Strong momentum in stock performance
- Graded A- for 2026 potential
Cons:
- Negative one-year return
- Market volatility risk
Elevance Health (ELV) may be suitable for investors seeking a blend of growth potential and dividend income, particularly those with a long-term investment horizon given its solid 5-year return of 12% despite recent short-term volatility. With analysts projecting further price appreciation, this stock could appeal to both value and growth-focused investors looking for opportunities in the healthcare sector.